2025 Mar 14, 08:48
Microbot Medical Inc (MBOT) shares are surging today following the announcement of the successful completion of its GLP pivotal pre-clinical study. The study, conducted by three interventional radiologists, involved the use of Microbot's LIBERTY Endovascular Robotic Surgical System to perform 96 robotic navigations, all of which met the objectives outlined by the FDA. With these promising results, Microbot is now ready to move on to human studies and plans to submit an Investigational Device Exemption (IDE) application to the FDA in the near future. Juan Diaz Cartelle, the chief medical officer of Microbot, expressed his satisfaction with the study's outcomes, stating that they provide the company with confidence to progress to the next stage of human clinical studies. The news of Microbot's successful study has garnered attention on various social platforms and this increased exposure might be contributing to the surge in retail trading activity surrounding the stock. At the time of publication, Microbot shares were up 40% at $1.85. As we await further updates from Microbot and its progress towards becoming a clinical-stage company, it is worth considering the overall investment climate
The 60/40 portfolio, for example, has recently rebounded from a slump in 2022, prompting discussions about whether it remains a suitable investment strategy for 2024. (Photo by StockSnap from Pixabay)